| Title |
S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB–C Melanoma
|
|---|---|
| Published in |
Annals of Surgical Oncology, March 2013
|
| DOI | 10.1245/s10434-013-2949-y |
| Pubmed ID | |
| Authors |
K. P. Wevers, S. Kruijff, M. J. Speijers, E. Bastiaannet, A. C. Muller Kobold, H. J. Hoekstra |
| Abstract |
In melanoma patients with nodal macrometastases, the distinction between good and poor prognosis is based on the presence of primary melanoma ulceration or metastatic involvement of 4 or more lymph nodes in the 7th edition of the American Joint Committee on Cancer (AJCC) classification. We hypothesized that biomarkers would increase the accurateness of staging in these patients. The aim was to assess and compare the prognostic impact of biomarkers S-100B and LDH and to determine the best timing of their measurement in stage IIIB-C melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 4% |
| Turkey | 1 | 4% |
| Unknown | 21 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 26% |
| Student > Ph. D. Student | 4 | 17% |
| Student > Doctoral Student | 3 | 13% |
| Researcher | 3 | 13% |
| Other | 2 | 9% |
| Other | 2 | 9% |
| Unknown | 3 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 35% |
| Biochemistry, Genetics and Molecular Biology | 5 | 22% |
| Agricultural and Biological Sciences | 4 | 17% |
| Neuroscience | 1 | 4% |
| Unknown | 5 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2019.
All research outputs
#5,145,740
of 25,090,809 outputs
Outputs from Annals of Surgical Oncology
#1,637
of 7,163 outputs
Outputs of similar age
#40,479
of 202,643 outputs
Outputs of similar age from Annals of Surgical Oncology
#8
of 40 outputs
Altmetric has tracked 25,090,809 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,163 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,643 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.